Ipsen delivers strong sales momentum in the first nine months of 2024 and increases its full-year guidance

PARIS, FRANCE, 23 October 2024 - Ipsen ((Euronext: IPN, OTC:IPSEY), a global specialty-care biopharmaceutical company, today presents its performance for the year to date and the third quarter of 2024.

   

YTD 2024

YTD 2023

% change

Q3 2024

Q3 2023

% change

€m

€m

Actual

CER1

€m

€m

Actual

CER1

Oncology

1 829,8

1 744,1

4,9%

5,8%

604,0

574,5